Shi, W.; Li, C.; Wartmann, T.; Kahlert, C.; Du, R.; Perrakis, A.; Brunner, T.; Croner, R.S.; Kahlert, U.D.
Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents. J. Pers. Med. 2022, 12, 478.
https://doi.org/10.3390/jpm12030478
AMA Style
Shi W, Li C, Wartmann T, Kahlert C, Du R, Perrakis A, Brunner T, Croner RS, Kahlert UD.
Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents. Journal of Personalized Medicine. 2022; 12(3):478.
https://doi.org/10.3390/jpm12030478
Chicago/Turabian Style
Shi, Wenjie, Chen Li, Thomas Wartmann, Christoph Kahlert, Renfei Du, Aristotelis Perrakis, Thomas Brunner, Roland S. Croner, and Ulf D. Kahlert.
2022. "Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents" Journal of Personalized Medicine 12, no. 3: 478.
https://doi.org/10.3390/jpm12030478
APA Style
Shi, W., Li, C., Wartmann, T., Kahlert, C., Du, R., Perrakis, A., Brunner, T., Croner, R. S., & Kahlert, U. D.
(2022). Sensory Ion Channel Candidates Inform on the Clinical Course of Pancreatic Cancer and Present Potential Targets for Repurposing of FDA-Approved Agents. Journal of Personalized Medicine, 12(3), 478.
https://doi.org/10.3390/jpm12030478